August 5th 2024
A year after zuranolone’s FDA approval for postpartum depression on August 3, 2023, prescribers and a patient weigh in about the medication’s success in alleviating symptoms.
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Mind-body resilience for women: A focus on depression
Here’s why we should be paying special attention to women’s depression treatment.
Read More